Limited said that it will design and implement the Research Informatics System
(RISe) at Elan Pharmaceuticals, Inc, a leading biotechnology company, to
accelerate discovery research using a path-breaking co-creation engagement
model that leverages Infosys’ existing intellectual property in this field.
"We are confident that
partnering and collaborating with Infosys will create a comprehensive
informatics platform for our discovery research needs," said Ajay Shah,
Director – Research Informatics, Elan Pharmaceuticals. "We selected
Infosys after a competitive Proof-of-Concept phase during which they fully
established their credentials and investments in this changing field of discovery
research, and demonstrated flexibility and maturity in terms of rapid
application development using Agile and Scrum methodologies. With Infosys’
solution and engagement model, Elan will be able to lower costs for scientific
operation and facilitate innovation.
As Elan’s informatics
system, RISe will leverage Infosys’ Scientific Innovation Solution for
knowledge collaboration. Novel ways to unlock disparate data spread across
in-house research labs and other commercial or public sources will be presented
to scientists in context of their research needs. This will result in, among
other things, a customized registry, and inventory and a workflow management
system for biological entities.
Elan and its research
partners could realize significant gains in research productivity by focused
and efficient selection of candidate drugs or biologics with the new RISe.
Linking silos of heterogeneous data will not only contribute to a more
effective selection process of biologics but could also reduce time to validate
them clinically. Furthermore, the new system will reduce time spent on
registering and experimenting with bio-entities, increase collaboration, and
reduce chances of downstream failure.
Future versions of the
software may enable integration of RISe with electronic lab notebook and
analytical dashboards which will enable more efficient research knowledge
The co-creation engagement
model enables Infosys to retain ownership of co-developed IP as part of the
implementation. Relevant components of this reference implementation can be
reused or repurposed by Infosys to deliver faster business benefits at other
Life Sciences organizations.
"Elan’s vision to
create a scalable research informatics system for scientists to collaborate
better, dovetails perfectly with our investments in solutions that improve
scientific innovation and our efforts to streamline discovery research,"
said R Arun Kumar, head of Infosys’ Global Life Sciences Practice, Infosys